Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPhysical Medicine, Rehab & Therapiesamerican_specialty_health Laser Therapy Coverage U…
    Ask Trek AI about this page
    Currentamerican_specialty_healthPolicy N/A

    Therapy Services — Low-Level Laser and High-Power Laser Therapy

    Customize your policy alerts

    Sign up for all american_specialty_health policy alerts

    Know when american_specialty_health releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Defines medical coverage and criteria for low-level laser therapy and high-power (Class IV) therapeutic laser light therapy for Cigna-administered benefit plans; intended for providers who bill these services.

    Policy Summary
    Payeramerican_specialty_health
    PolicyTherapy Services — Low-Level Laser and High-Power Laser Therapy
    Policy CodePolicy N/A
    Change TypeNo material changes
    Effective DateMar 15, 2026
    Next Review DateMar 15, 2027
    Key ActionWhen seeking coverage, document diagnosis, prior conservative therapies, planned laser parameters and treatment schedule; bill using the most appropriate covered codes.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    1Medically necessary indication
    MultipleNot medically necessary/experimental
    CPT/HCPCSCodes listed
    multipleSystematic reviews

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    6
    Conditions discussed
    mixedEvidence direction

    Coverage Criteria

    Medically Necessary Indication

    Covered when ALL of the following are met:

    Prevention of oral mucositis: Low-level laser therapy is considered medically necessary for prevention of oral mucositis in patients undergoing cancer treatment associated with increased risk of oral mucositis, including chemotherapy and/or radiotherapy, and/or hematopoietic cell transplantation.

    Use applicable covered codes when billing (e.g., CPT 97037, 0552T; HCPCS S8948).

    Not Medically Necessary / Experimental

    Not medically necessary for any other indication, including but not limited to:

    LLLT not medically necessary: Low-level laser therapy (LLLT) is considered not medically necessary for indications other than prevention of oral mucositis, including but not limited to: wound healing; musculoskeletal pain (e.g., back and neck pain, carpal tunnel syndrome, lateral epicondylitis, shoulder impingement, myofascial pain syndrome, fibromyalgia); osteoarthritis and rheumatoid arthritis; temporomandibular joint disorders; and other indications not specified as covered.
    High-power Class IV HILT: High-power Class IV therapeutic laser light therapy or similar therapeutic laser light therapy is considered experimental, investigational, and/or unproven for all indications.

    Report high-power HILT with unlisted modality code (97039) which is considered experimental/investigational under this policy.

    Evidence summaries by condition

    Condition-specific evidence summaries and implied coverage considerations

    Knee osteoarthritis (KOA): LLLT and HILT may reduce pain when used as adjuncts to exercise; indirect comparisons suggest HILT+exercise may have greater efficacy for pain and stiffness but certainty is low to very low; optimal dosing needs standardization (e.g., LLLT 4–8 J per point, 640–905 nm, 10–16 sessions at ~2 sessions/week).

    Evidence from Malik et al. 2023 and Ahmad et al. 2022; document exercise adjunct.

    Thumb CMC osteoarthritis: Small RCT evidence suggests HILT can reduce pain intensity as an isolated treatment for thumb CMC OA, but effects may diminish by 12 weeks.

    Ahmad et al. and cited small trials report short-term benefit.

    Shoulder pain / subacromial impingement / frozen shoulder: Systematic reviews are inconsistent; some trials report benefit when optimal dosing used. HILT added to physical therapy may reduce pain and disability for frozen shoulder and subacromial impingement versus conventional therapy for certain outcomes, though range-of-motion effects are inconsistent.

    Trials and meta-analyses (de la Barra Ortiz 2023; Hao 2024) provide mixed evidence.

    Evidence summaries by condition (additional)

    Evidence summaries by condition (no explicit AND/OR criteria in these chunks).

    Low back pain evidence: Some RCTs and reviews report short-term pain and function improvement with HILT/LLLT; AHRQ review notes low strength of evidence and generally small effect sizes; many trials are small and long-term data are sparse.

    Choi 2017; Abdildin 2023; AHRQ update referenced.

    Neck pain evidence: Systematic reviews are inconsistent; moderate-quality evidence supports short-term pain/function improvement with LLLT for chronic neck pain in some reviews, while other analyses highlight heterogeneity and risk of bias.

    Chow 2009; Gross 2013; NICE and recent meta-analyses cited.

    Plantar fasciitis: Multiple systematic reviews report LLLT/PBMT reduces short-term pain and sometimes disability; evidence is typically short- to medium-term with limited long-term data.

    Guimarães 2022/2023; Ferlito 2023; Yadav 2025.

    Oral mucositis — guideline-supported prevention

    Covered when aligned with guideline recommendations and evidence-based protocols:

    Oral mucositis prevention in specific oncology settings: Intraoral photobiomodulation (PBM)/LLLT is supported by MASCC/ISOO guidelines for prevention of oral mucositis in patients undergoing hematopoietic stem cell transplantation (HSCT) and in patients receiving head and neck radiotherapy (with or without chemotherapy).

    PBM protocols described in the guideline should be followed exactly; clinicians should inform patients about benefits and potential tumor-related uncertainties.

    TMD/TMJ — mixed evidence and conditional guideline stance

    Evidence for TMD/TMJ and orofacial pain — heterogeneous findings with some short-term benefits:

    TMD pain relief evidence: Multiple systematic reviews and RCTs report that LLLT/PBM can reduce short-term pain and may improve mandibular function or mouth opening in TMD; effect sizes and optimal parameters vary across studies (wavelengths, dosages), and evidence certainty ranges from low to moderate.

    Xu 2018; Ahmad 2021; de Oliveira-Souza 2023; Ren 2022; Maia 2012.

    Comparative effectiveness: Network and comparative studies found LLLT may rank well for improving maximum mouth opening in disc displacement with reduction, while other interventions (e.g., arthrocentesis with PRP/HA) ranked higher for pain reduction; overall evidence is generally very low quality and guideline panels have issued conditional recommendations against routine use for chronic TMD pain.

    Al-Moraissi 2024; guideline caution noted.

    Wound healing — promising but low-certainty evidence

    Wound healing and diabetic foot ulcers — adjunctive benefit reported with low certainty:

    Diabetic foot ulcers and wound healing: Meta-analyses report that red/infrared light or LLLT may increase complete healing rates, reduce ulcer area and healing time in diabetic foot ulcers; HILT shows promising results in small studies. However, study quality and sample sizes limit certainty and evidence is graded low to very low.

    Huang 2021; Liu 2023; Zhang 2024; Yoon 2024 emphasize limited sample sizes and need for higher-quality trials.

    Oral mucositis — supportive evidence and guideline recommendation

    Summary of clinical evidence and guideline recommendations captured in this document portion (no explicit stepwise authorization criteria provided here).

    Oral mucositis (OM): Multiple systematic reviews and RCT meta-analyses report that PBMT/LLLT reduces incidence, severity, and pain of cancer therapy–induced oral mucositis in adults and pediatric patients. Updated MASCC/ISOO guidelines recommend intraoral PBM for HSCT and head & neck radiotherapy patients; protocol adherence and parameter reporting are emphasized for effectiveness.

    He 2018; de Lima 2020; Patel 2021; Lalla/MASCC guidance; multiple 2022–2025 reviews summarized.

    Musculoskeletal conditions — evidence summary

    Evidence for musculoskeletal indications shows mixed but sometimes positive results depending on adherence to dosing guidelines and specific conditions.

    Musculoskeletal pain and function: Systematic reviews and meta-analyses report LLLT/PBMT and HILT can reduce pain and improve disability in select musculoskeletal disorders (knee OA, back/neck pain, tendinopathy, plantar fasciitis, ankle sprain) when dosing adheres to guidelines (e.g., WALT); heterogeneity and variable study quality limit broad conclusions.

    Clijsen 2017 showed larger effects when WALT dosing used; NICE and Song et al. provide mixed recommendations.

    Other conditions — lymphedema, neuropathy, acute pain

    Evidence for other conditions is variable and often low quality.

    Other indications: For painful diabetic neuropathy, guideline evidence suggests LLLT is probably not effective and is not recommended. For breast cancer–related lymphedema, systematic reviews report conflicting or low-to-very-low quality evidence with some trials showing reduced limb volume but inconsistent functional benefit. Acute postoperative pain and ankle sprain show some positive findings but require higher-quality studies.

    Bril 2011 guideline and Wang/Mahmood/Chiu reviews summarized.

    This policy does not address surgical lasers (hot lasers) that vaporize tissue; those devices and procedures are outside the scope of this coverage policy and are not evaluated here.

    Available evidence does not support recommending photobiomodulation/low‑level laser therapy (PBM/LLLT) as an isolated, stand‑alone treatment for knee osteoarthritis or most other musculoskeletal or wound indications. PBM/LLLT may be considered only as an adjunct to guideline‑recommended therapies in selected cases where evidence shows benefit (for example, when combined with exercise in some trials), and documentation should demonstrate concurrent conservative care and adherence to protocol parameters cited in the literature.

    The reviewed literature and systematic reviews do not list specific procedural or diagnosis exclusions in a prescriptive way; instead, they emphasize heterogeneity of study populations, variable protocols, and generally insufficient high‑quality evidence to support broad routine coverage for many indications (e.g., RA, some tendon disorders). Coverage determinations therefore follow condition‑specific evidence strength rather than enumerated procedural exclusions.

    A comparative‑effectiveness guideline panel addressing chronic temporomandibular disorder (TMD) pain issued conditional recommendations against the use of low‑level laser therapy, either alone or in combination with other interventions, for patients with chronic (≥3 months) TMD pain; the guideline advises prioritizing strongly recommended conservative therapies first.

    A multi‑society guideline for painful diabetic neuropathy concluded that LLLT is probably not effective for this indication and therefore is not recommended, indicating that routine use for diabetic neuropathy is not supported by current guideline evidence.

    The sections labeled as references do not by themselves state explicit coverage exclusions or medical‑necessity determinations; they list source studies and reviews that inform the policy but do not make standalone coverage statements in this portion of the document.

    The bibliography entries compiled in these chunks are reference citations only and do not include independent coverage exclusions or policy determinations; they support the evidence summaries referenced elsewhere in the policy.

    Within this policy the overall determinations are: LLLT/PBM is not medically necessary for indications other than prevention of oral mucositis, while high‑power Class IV HILT is considered experimental, investigational, and/or unproven for all indications. This summary reflects the policy's stance based on the evidence reviews and guideline recommendations cited.

    Across multiple conditions the evidence is inconsistent and often of low or insufficient strength; therefore the policy cautions against routine use of laser therapies for many indications (for example, acute low back pain, some shoulder and carpal tunnel studies) unless supported by robust, protocol‑adherent evidence and appropriate documentation of prior conservative care.

    For rheumatoid arthritis the literature is conflicting and of generally low quality; systematic reviews and recent analyses found that infrared laser may not be superior to sham, so current evidence does not support routine use of LLLT for RA.

    Because the comparative‑effectiveness panel issued conditional recommendations against LLLT for chronic TMD pain, use of low‑level laser therapy for chronic TMD is likely to be viewed unfavorably in guideline‑driven contexts and may not be routinely covered.

    For breast cancer–related lymphedema and other wound‑healing indications, systematic reviews report conflicting results and generally low to very low quality evidence; while some small trials report reductions in limb volume or ulcer metrics, the overall uncertainty means routine coverage without stronger, consistent evidence is not supported.

    These reference‑only chunks compile citations and do not, by themselves, state explicit not medically necessary determinations; they serve as the evidence base cited throughout the policy rather than standalone policy statements.

    The reference list entries in this portion of the document are bibliographic and do not include independent policy language or explicit "not medically necessary" rulings; they provide the sources used to support the policy's condition‑based conclusions.

    Coding

    Considered Medically Necessary CPT Codes (when criteria met)CPTCovered
    97037Application of a modality to 1 or more areas; low-level laser therapy (ie, nonthermal and non- ablative) for post-operative pain reduction
    0552TLow-level laser therapy, dynamic photonic and dynamic thermokinetic energies, provided by a physician or other qualified health care professional
    Considered Medically Necessary HCPCSHCPCSCovered
    S8948Application of a modality (requiring constant provider attendance) to one or more areas; low-level laser; each 15 minutes
    Considered Experimental/Investigational/Unproven coding for high-power HILTCPTExperimental
    97039Unlisted modality (specify type and time if constant attendance) — used to report high-power Class IV therapeutic laser light therapy
    Devices listed in FDA 510(k) summariesmixed
    device examples (not billing codes)MicroLight 830, Thor Laser System, Luminex LL, Vectra Genisys, Diawave/AVI HP-7.5/AVI HPLL-12, Zimmer OptonPro (FDA 510(k) devices)
    WALT power density and energy dose guidance — Power density and energy dosing guidance (WALT) for superficial and deeper tendons and wavelength ranges
    Superficial tendons (WALT guidance)Power density <100 mW/cm2; energy dose 1–8 J per site; wavelength range 780–904 nm
    Deeper tendons (WALT guidance)Power density up to 600 mW/cm2; energy dose 3–9 J per site; wavelength range 780–904 nm
    Purpose of WALT parametersDefined to allow selective analysis of studies that adhere to recommended power density and energy dosing for effectiveness evaluation
    LLLT dosing for KOA per cited studies — Dosing parameters (4-8 J per point, wavelength 640-905 nm, 10-16 sessions) as reported in cited KOA studies
    Energy per point4–8 J per point

    Provider Actions and Billing

    Billing Rule

    Bill with appropriate covered codes — non‑covered codes will be denied

    When billing for laser therapy, providers must use the most appropriate procedure codes effective on the date of service; claims submitted for services that are not accompanied by covered code(s) under this policy will be denied as not covered.

    • Use covered codes when criteria met (examples in policy coding: 97037, 0552T, S8948).
    • Unlisted high‑power HILT should be reported with 97039 per policy coding guidance (97039 is considered experimental/investigational).
    Prior Authorization

    Prior authorization recommended — include diagnosis, prior conservative care, and laser parameters

    When laser therapy is requested as a course of treatment, prior authorization should document the diagnosis, prior conservative therapies, and planned laser parameters and treatment schedule.

    Background

    The one indication supported for coverage in this policy is intraoral PBM/LLLT for prevention of cancer therapy–related oral mucositis in specified oncology settings; when used for this indication clinicians should follow MASCC/ISOO guideline protocols and document adherence to the recommended parameters.

    Definitions

    LLLT / High Power Class IV HILT — Definitions and distinguishing features for LLLT and high-power Class IV HILT
    LLLT (Low-level laser therapy)Nonthermal, low-power/low-intensity/low-energy laser modalities intended to be non‑ablative and used to photoactivate cellular mechanisms to reduce pain and promote tissue repair
    High Power Class IV HILTHigher-power Class IV therapeutic laser light therapy producing continuous high milliwatt output (manufacturer example: ~7,500 mW) intended for deeper tissue penetration and larger surface treatment area
    Distinguishing featuresLLLT: low continuous power, nonthermal effects; HILT: high continuous power, deeper penetration, marketed for broader musculoskeletal indications
    Photobiomodulation (PBM) / LLLT — Definition and typical wavelength/energy parameters
    DefinitionPhotobiomodulation (PBM) / LLLT: low-intensity light therapy using specific wavelengths to modulate inflammation and cellular repair processes
    Policy Summary
    Payeramerican_specialty_health
    PolicyTherapy Services — Low-Level Laser and High-Power Laser Therapy
    Policy CodePolicy N/A
    Change TypeNo material changes
    Effective DateMar 15, 2026
    Next Review DateMar 15, 2027
    Key ActionWhen seeking coverage, document diagnosis, prior conservative therapies, planned laser parameters and treatment schedule; bill using the most appropriate covered codes.
    SourceLink
    On This Page
    Coverage CriteriaCodingProvider Actions and BillingBackgroundDefinitions
    Carpal tunnel syndrome (CTS): Evidence is inconsistent: some meta-analyses report short-term advantages for pain and grip strength and very short-term benefit (≤5 weeks); other analyses show no clinically meaningful long-term benefit; LLLT plus splinting may slightly reduce pain but not function.

    AAOS and Cochrane summaries note limited/low-quality evidence.

    Myofascial pain / mechanical neck pain: RCTs yield mixed results; meta-analyses suggest LLLT/PBMT can reduce pain and increase pain pressure threshold, especially when combined with exercise, but disability outcomes are less consistent.

    Evidence includes Carrasco 2009, Rayegani 2011 and broader neck pain reviews.

    Low back pain (acute and chronic): Systematic reviews report inconsistent findings; some trials report short-term pain reduction with LLLT/HILT (including HILT combined with exercise) but overall strength of evidence ranges from insufficient to low; function improvements are generally small and longer-term data sparse.

    AHRQ and Choi/Abdildin reviews referenced; effect sizes generally small.

    Achilles tendinopathy: Some small trials report benefit when LLLT is added to eccentric exercise but overall evidence is low to very low and insufficient for routine use.

    Stergioulas 2008; Tumilty 2008; Martimbianco 2020; APTA guidance.

    Lateral epicondylitis: Systematic reviews are inconsistent; some trials show short-term pain relief and function improvement, but overall evidence is insufficient to conclude consistent effectiveness.

    Bjordal 2008 and later reviews show mixed findings.

    Rheumatoid arthritis: Reviews show conflicting or low-quality evidence; infrared laser may not be superior to sham and routine use is not supported by high-quality evidence.

    Cochrane 2005; Lourinho 2023.

    Temporomandibular disorders (TMD) and orofacial pain: Multiple systematic reviews and RCTs show mixed results; several report short-term pain relief and some functional gains, but heterogeneity in protocols and inconsistent findings limit confidence.

    Xu 2018; de Oliveira-Souza 2023; numerous recent reviews.

    Wavelength range640–905 nm
    Treatment courseApplied for 10–16 sessions at approximately 2 sessions per week
    • Include diagnosis and reason for treatment.
    • Describe prior/concurrent conservative treatments (e.g., exercise, splinting) and prior trial outcomes.
    • Provide laser parameters (wavelength, joules per point, number/frequency of sessions) and planned schedule.
    Note

    No specific prior authorization requirements specified in this excerpt

    This excerpt does not specify mandatory prior authorization requirements or list payer-specific affected billing codes; check the applicable benefit plan or payer prior‑auth rules.

    Prior Authorization

    Prior authorization recommendation for PBM in oral mucositis — reference MASCC/ISOO protocols

    For intraoral PBM/LLLT to prevent oral mucositis in patients undergoing HSCT or head & neck radiotherapy, documentation should reference MASCC/ISOO guideline‑recommended indication and protocols when seeking authorization.

    • Document that treatment follows the MASCC/ISOO intraoral PBM protocol for OM prevention.
    • Specify patient population (HSCT or head & neck RT with/without chemotherapy) and cite the guideline recommendation.
    Prior Authorization

    Device/indication prior authorization — provide device model and 510(k) info

    If a payer requires prior authorization for use of a specific laser device, provide the device model, FDA 510(k) clearance information, indication, treatment parameters, and supporting clinical evidence.

    • Include device model and FDA 510(k) clearance summary or documentation.
    • Provide indication‑specific rationale and cited clinical evidence supporting use for that indication.
    Note

    No prior authorization statements in references section

    No prior authorization statements are included in the references section of this policy excerpt.

    Note

    No prior authorization requirements in reference‑only chunks

    The reference‑only chunks do not specify prior authorization requirements.

    Note

    (no content)

    No content provided for this inventory placeholder.

    Step Therapy

    Require trial of conservative therapy before laser authorization

    Consider documenting trials of standard conservative care (e.g., exercise therapy, splinting for CTS, education/self‑management for lumbar disc herniation) prior to authorization of laser therapy, since most evidence evaluates laser as an adjunct to these treatments.

    • Document duration and response to conservative therapies.
    • Note concurrent rehabilitation or exercise programs when laser is used as an adjunct.
    Note

    (no content)

    No content provided for this inventory placeholder.

    Step Therapy

    Stepwise care for chronic TMD — document first‑line conservative treatments first

    For chronic temporomandibular disorder (TMD), guideline panels recommend first‑line conservative treatments (e.g., CBT, supervised jaw exercise, occlusal splints) before interventions that received conditional recommendations against them; document prior use of recommended conservative therapies if requesting laser treatment.

    • Document use and outcomes of first‑line therapies (CBT, exercise, splints) prior to considering LLLT.
    Step Therapy

    Document prior conservative care for musculoskeletal indications

    For musculoskeletal conditions, document prior conservative care such as exercise or multimodal rehabilitation because reviews recommend laser therapy be considered as part of a multimodal approach.

    • Specify type and duration of prior rehabilitation or exercise program and patient response.
    • Indicate whether laser is intended as an adjunct to ongoing multimodal therapy.
    Note

    References do not add extra provider actions

    References cited in this section do not specify additional operational provider actions beyond those already stated.

    Note

    No step therapy requirements specified in references

    No step therapy requirements are specified in the referenced chunks.

    Documentation Required

    Required documentation elements — diagnosis, parameters, pre/post observations, outcomes

    Documentation should include the diagnosis/reason for treatment, duration and specific laser parameters used, area treated, observations pre‑ and post‑treatment, and demonstration of improvement or lack thereof to support medical necessity.

    • Record treatment dates, number and frequency of sessions, and objective/subjective outcome measures.
    • Include pre/post observations and functional change documentation.
    Documentation Required

    Document clinical details — diagnosis, rehab, and exact laser parameters

    Recommended clinical documentation should include diagnosis, prior or concurrent exercise/rehabilitation when applicable, specific laser parameters (wavelength, joules per point, number and frequency of sessions), and follow‑up outcomes because efficacy is often dose‑ and protocol‑dependent.

    • Specify wavelength and joules per point (e.g., LLLT 4–8 J per point for KOA where cited).
    • Include number of sessions and frequency (e.g., 10–16 sessions at ~2/wk for KOA studies).
    Note

    (no content)

    No content provided for this inventory placeholder.

    Documentation Required

    Protocol adherence and informed consent for PBM in OM prevention

    If providing PBM/LLLT for prevention of oral mucositis, clinicians should follow the PBM protocols described in the MASCC/ISOO guidelines and document informed consent noting expected benefits and any tumor‑related uncertainties.

    • Document adherence to MASCC/ISOO intraoral PBM protocol.
    • Obtain and document informed consent discussing benefits and uncertainties.
    Documentation Required

    Document laser protocol parameters (wavelength, fluence, site, frequency) and cite sources

    Document adherence to published PBMT/LLLT parameter protocols (wavelength, fluence/energy, treatment site, and frequency) and cite guideline or WALT sources when applicable, since adherence to recommended dosages is associated with better outcomes.

    • Record wavelength, energy per point, power density, and number/frequency of applications.
    • Cite WALT or guideline‑consistent dosing where used.
    Note

    References-only chunks — no additional documentation requirements

    Reference sections do not add operational documentation requirements beyond those already specified.

    Note

    Reference list — no operational documentation requirements

    Reference list chunks do not specify operational documentation requirements for providers.

    Denial Risk

    Claims without covered codes will be denied

    Claims submitted for services that are not accompanied by covered code(s) under this policy will be denied as not covered.

    Denial Risk

    Inadequate/undefined dosing or missing parameter documentation risks denial

    Trials performed with inadequate laser doses were ineffective; unclear or suboptimal dosing or omission of parameter documentation may lead to lack of benefit and potential denial risk if parameter details are not provided.

    • Ensure documentation includes dosimetry (e.g., joules per point) and adherence to recommended dosing when applicable.
    • Note that studies noted ineffective results when inadequate doses were used.
    Note

    No explicit authorization or denial triggers in these chunks

    Not applicable in this excerpt — no explicit authorization or denial triggers are stated in these reference chunks.

    Denial Risk

    Guideline‑based denial risk for chronic TMD

    Guideline panels issued conditional recommendations against low‑level laser therapy (alone or in combination) for chronic TMD pain, indicating use for chronic TMD may be at higher risk for noncoverage or denial in some contexts.

    • Document prior first‑line treatments and rationale if requesting LLLT for chronic TMD.
    Denial Risk

    Evidence/device limitations may increase denial risk

    Use of devices or treatments without demonstrated peer‑reviewed evidence of benefit, or use outside accepted protocols, may be at risk for noncoverage given variable evidence and FDA 510(k) approvals based on summaries rather than published trials.

    • Provide peer‑reviewed evidence when requesting coverage for a specific device/indication.
    • If device evidence is limited to 510(k) summaries, anticipate heightened scrutiny.
    Note

    Reference sections — no operational provider requirements

    Reference sections list citations only and do not state operational authorization requirements.

    Note

    Reference‑only chunks — no provider authorization requirements

    Reference list chunks do not state provider authorization requirements.

    Typical wavelengthsExamples cited include 640–905 nm (musculoskeletal studies) and 620–750 nm for intraoral PBM in mucositis prevention
    Typical energy/doseCommonly reported dosing in trials: ~4–8 J per point for musculoskeletal applications; many protocols specify joules per point and sessions to achieve effect
    High-intensity laser therapy (HILT) — Definition and intended clinical use
    DefinitionHigh-intensity laser therapy (HILT): higher-power laser modality used for deeper tissue penetration and proposed to reduce pain and disability in conditions such as OA, back/neck pain, and radiculopathy
    Intended clinical useStudied as an adjunct to exercise/physical therapy for conditions like knee OA, frozen shoulder, cervical radiculopathy and chronic back pain to improve pain and function
    Evidence and parameters variabilityParameters and evidence vary across studies; some trials report short- to medium-term benefit but further research is needed for long-term effectiveness
    Low-level laser therapy (LLLT) — Therapeutic intent and common usage in trials
    Therapeutic intentLow-level laser therapy (LLLT) aims to reduce pain, inflammation and improve function via nonthermal photobiomodulation mechanisms
    Common usage in trialsApplied as adjunct to exercise or rehabilitation in RCTs for musculoskeletal disorders (e.g., KOA, tendinopathy, neck/back pain)
    Protocol dependenceEffectiveness often linked to adherence to dosing guidelines (e.g., WALT); heterogeneity of devices and protocols noted across studies
    High-intensity laser therapy (HILT) — Studies showing possible short-term benefits in some conditions
    Short-term benefits reportedSome studies of HILT report short- to medium-term reductions in pain and disability (e.g., frozen shoulder, subacromial impingement, cervical radiculopathy)
    Adjunct to rehabilitationHILT has been studied combined with exercise or conventional physical therapy, often showing greater improvements than control interventions in selected trials
    Certainty and durationReported benefits may diminish over time (e.g., effects decreasing by 12 weeks in some trials); evidence certainty often low to moderate
    Photobiomodulation (PBM) — Term definition and interchangeability with LLLT
    Term definitionPhotobiomodulation (PBM) encompasses low-level laser or light therapy applied intraorally or externally to modulate tissue response for prevention or treatment (e.g., oral mucositis)
    Interchangeability with LLLTGuidelines and reviews use PBM and LLLT interchangeably; PBM is the broader term capturing low-intensity laser/light therapies
    Protocol emphasisGuideline recommendations (MASCC/ISOO) for PBM specify exact protocols and parameter adherence to achieve preventive effects in oral mucositis
    High-intensity laser therapy (HILT) — Additional definition entry from inventory
    Definition (additional)High-intensity laser therapy (HILT): marketed high-power systems (Class IV) intended to increase circulation, decrease inflammation, relax muscle spasm, accelerate tissue repair and reach deeper tissues than LLLT
    Device examples / regulatory contextHigh-power systems have FDA 510(k) clearances (e.g., Diawave/AVI HP-7.5, AVI HPLL-12, Zimmer OptonPro) but parameters and peer-reviewed supporting trials vary
    Photobiomodulation therapy (PBMT) / LLLT — Non-invasive single-wavelength light therapy definition and intent
    DefinitionPhotobiomodulation therapy (PBMT) / LLLT: non‑invasive application of a single wavelength of light (laser or LED) to tissue aimed at reducing pain, inflammation and promoting healing
    Delivery settingsUsed intraorally (e.g., oral mucositis prevention) or externally for musculoskeletal conditions; delivered by various providers in outpatient settings
    Device/parameter variabilityDevices include laser diodes and LEDs with varied wavelengths and dosing; trials report diverse parameters, necessitating protocol adherence for reproducible effects
    LLLT / Photobiomodulation — General descriptive definition
    General descriptionLLLT/Photobiomodulation: low-power, nonthermal light therapy intended to stimulate cellular activity, reduce pain and support tissue repair
    Clinical research contextNumerous RCTs and systematic reviews exist but heterogeneous in methods, instruments and parameters, complicating general conclusions
    Photobiomodulation / LLLT — Definition as referenced across multiple reviews and trials
    Widely referenced definitionPhotobiomodulation / LLLT refers to low-intensity laser/light therapy used across systematic reviews and randomized trials for pain, wound healing, and inflammation
    Research implicationsEffectiveness is often dose- and protocol-dependent; WALT guidelines are frequently cited to standardize parameters in trials